Pharmacological treatment of combatinduced PTSD: a literature review

Historically, soldiers have returned from war changed men. Over the years there has been an increase in awareness of post-traumatic stress disorder (PTSD) and the impact of diagnosis. Treatment of PTSD presents a challenge on every level. This literature review provides some insight into the risks and benefits of three groups of drugs commonly prescribed for combat-induced PTSD: beta-blockers, selective serotonin reuptake inhibitors (SSRIs) and benzodiazepines (BZDs). When prescribed in conjunction with other non-pharmacological treatments, these drugs help to minimize, and in some cases eliminate, the signs and symptoms of PTSD. Combination therapy would ideally result in better compliance and eventual completion of treatment programmes provided for PTSD sufferers. Healthcare professionals strive to provide patients with holistic care. Patients present with unique mental and physical intricacies, and nurses and health professionals must peel away the layers to uncover the nature of the PTSD. While there are many aspects to PTSD treatment, this literature review focuses on pharmacological treatment, specifically beta-blockers, SSRIs and BZDs.